Cargando…

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks

Pasteurella multocida can invade and translocate through endothelial cells and result in vascular-system infection, which can cause severe economic losses in the poultry industry. Antibacterial therapy (especially florfenicol) plays an important part in controlling P. multocida infection. To preserv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Xia, Lan, Weixuan, Zhao, Yaqin, Li, Ruichao, Liu, Yuan, Liu, Juan, Wang, Zhiqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829356/ https://www.ncbi.nlm.nih.gov/pubmed/33505384 http://dx.doi.org/10.3389/fmicb.2020.616685

Ejemplares similares

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against Pasteurella multocida and Haemophilus parasuis in Piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2022)

Integrated pharmacokinetic–Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets
por: Zeng, Qing Lin, et al.
Publicado: (2017)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2018)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against Streptococcus suis in Pigs
por: Somogyi, Zoltán, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida
por: Dorey, Lucy, et al.
Publicado: (2017)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
por: Wang, Rui-Ling, et al.
Publicado: (2022)

PK/PD integration of florfenicol alone and in combination with doxycycline against Riemerella anatipestifer
por: Zhang, Huilin, et al.
Publicado: (2022)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Optimization of florfenicol dose against Piscirickettsia salmonis in Salmo salar through PK/PD studies
por: San Martín, Betty, et al.
Publicado: (2019)

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model
por: Zhao, Yongda, et al.
Publicado: (2018)

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
por: Custodio, Joseph, et al.
Publicado: (2017)

Chinese ICU physicians’ knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey
por: Mao, Wenchao, et al.
Publicado: (2022)

Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
por: Weng, Yan, et al.
Publicado: (2015)

Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine
por: Sun, Da, et al.
Publicado: (2020)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Optimal Regimens and Cutoff Evaluation of Tildipirosin Against Pasteurella multocida
por: Lei, Zhixin, et al.
Publicado: (2018)

In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
por: Sun, Jian, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Gamithromycin Treatment of Pasteurella multocida in a Murine Lung Infection Model
por: Yang, Qingwen, et al.
Publicado: (2019)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

1560. Pharmacokinetics–Pharmacodynamics (PK-PD) of Gepotidacin (GEP) Against Escherichia coli in Murine Pyelonephritis and Thigh Infection Models
por: Barth, Aline, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Profiles of Tulathromycin in an Experimental Intraperitoneal Haemophilus parasuis Infection Model in Neutropenic Guinea Pigs
por: Guo, Li-li, et al.
Publicado: (2021)

Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model
por: Qu, Ying, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model
por: Zeng, Dongping, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model
por: Zhou, Qiaoyi, et al.
Publicado: (2017)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
por: Jitaree, Kamonchanok, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_98qqmii94bq8k6sn0m8gt5017g